Oncolytics Biotech Inc. (“Oncolytics”) (TSX:ONC, NASDAQ:ONCY) is pleased to announce that it has completed patient enrolment in its Phase I U.S. clinical trial investigating the systemic delivery of REOLYSIN(R) to treat patients with advanced cancers. A total of 18 patients were treated in the Phase I trial with REOLYSIN(R) at escalating dosages of 1x10(8), 3x10(8), 1x10(9), 3x10(9), 1x10(10) or 3x10(10) TCID(50). A maximum tolerated dose (MTD) was not reached and the treatment appears to have been well tolerated by the patients.
